Simcere Pharmaceutical Group (SCR)
Add to Watchlists Create an AlertSimcere Pharmaceutical Group EBITDA TTM
Simcere Pharmaceutical Group EBITDA TTM Chart
View EBITDA TTM for SCR.
Start Your YCharts Pro Gold Membership.
Simcere Pharmaceutical Group Historical EBITDA TTM Data
Pro Data ExportThere is no data for the selected date range.
About EBITDA (TTM)
EBITDA is an abbreviation for earnings before interest, taxes, depreciation, and amortization. EBITDA (TTM) is the sum of the last four quarters of EBITDA.
Investors often use EBITDA as a starting point for discounted cash flow analysis or to observe the performance of a business separately from its capital structure (debt vs equity financing structure).
Though EBITDA does form an excellent basis for cash flow analysis, some investors argue that it is a misleading measure since depreciation expenses are a real cost - old property, plant and equipment must eventually be replaced if a business plans to continue operations using those assets.
Learn More
View EBITDA TTM for SCR.
Start Your YCharts Pro Gold Membership.
Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle.
YCharts Pro is only $49/month, and comes with a 14-day free trial.
Get Started NowAlready a YCharts Pro Gold Member? Sign in here.
SCR EBITDA TTM Benchmarks
| Companies | |
|---|---|
| Bristol-Myers Squibb | Go Pro |
| Merck | Go Pro |
| Sagent Pharmaceuticals | Go Pro |
SCR EBITDA TTM Rankings
| Overall |
64th percentile 2688 of 7600 |
| Sector |
73rd percentile 175 of 653 in Healthcare |
| Industry |
74th percentile 17 of 66 in Drug Manufacturers - Specialty & Generic |